ES2571730T3 - Composiciones farmacéuticas que comprenden droxidopa - Google Patents

Composiciones farmacéuticas que comprenden droxidopa

Info

Publication number
ES2571730T3
ES2571730T3 ES11165693T ES11165693T ES2571730T3 ES 2571730 T3 ES2571730 T3 ES 2571730T3 ES 11165693 T ES11165693 T ES 11165693T ES 11165693 T ES11165693 T ES 11165693T ES 2571730 T3 ES2571730 T3 ES 2571730T3
Authority
ES
Spain
Prior art keywords
droxidopa
compounds
pharmaceutical compositions
combinations
inhibiting compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11165693T
Other languages
English (en)
Inventor
Michael J Roberts
Simon Pedder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LUNDBECK NA Ltd
Original Assignee
LUNDBECK NA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LUNDBECK NA Ltd filed Critical LUNDBECK NA Ltd
Application granted granted Critical
Publication of ES2571730T3 publication Critical patent/ES2571730T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una composición farmacéutica que comprende droxidopa en combinación con uno o más compuestos adicionales seleccionados del grupo que consiste en: entacapona; un inhibidor de la catecol-O-metiltransferasa que es específico para actividad periférica; y combinaciones de los mismos.
ES11165693T 2006-06-28 2007-06-28 Composiciones farmacéuticas que comprenden droxidopa Active ES2571730T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80603606P 2006-06-28 2006-06-28

Publications (1)

Publication Number Publication Date
ES2571730T3 true ES2571730T3 (es) 2016-05-26

Family

ID=38698773

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11165693T Active ES2571730T3 (es) 2006-06-28 2007-06-28 Composiciones farmacéuticas que comprenden droxidopa
ES07784556T Active ES2383768T3 (es) 2006-06-28 2007-06-28 Composiciones farmacéuticas que comprenden droxidopa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07784556T Active ES2383768T3 (es) 2006-06-28 2007-06-28 Composiciones farmacéuticas que comprenden droxidopa

Country Status (9)

Country Link
US (2) US20080015181A1 (es)
EP (3) EP2363124B1 (es)
AT (1) ATE548034T1 (es)
DK (1) DK1948155T3 (es)
ES (2) ES2571730T3 (es)
HR (1) HRP20120479T1 (es)
PL (1) PL1948155T3 (es)
PT (1) PT1948155E (es)
WO (1) WO2008003028A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158149B2 (en) 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
BRPI0808647A2 (pt) * 2007-03-09 2014-08-12 Chelsea Therapeutics Inc Método para tratar a síndrome de sensibilidade central, método para reduzir, eliminar ou prevenir a dor associada à fibromialgia, kit útil para o tratamento de uma síndrome de sensibilidade central.
WO2008112773A2 (en) * 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
ES2431570T3 (es) 2007-05-07 2013-11-27 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención
US8388656B2 (en) * 2010-02-04 2013-03-05 Ebi, Llc Interspinous spacer with deployable members and related method
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
EP2809315A1 (en) 2012-01-31 2014-12-10 Lundbeck Na Ltd Improving postural stability administering droxidopa
US20130253061A1 (en) 2012-03-20 2013-09-26 Chelsea Therapeutics, Inc. Method of droxidopa synthesis
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
AU2021289147A1 (en) 2020-06-12 2023-02-02 Beckley Psytech Limited Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
GB202008961D0 (en) * 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920728A (en) * 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
JPS5419931A (en) * 1977-07-11 1979-02-15 Sumitomo Chem Co Ltd Separation of threo, erythro-3-(3,4-dibenzyloxyphenyl)serines
US4319046A (en) * 1977-07-22 1982-03-09 The Sherwin-Williams Company Preparation of 1,2 diaminobenzene by high pressure acid hydrolysis of benzemidazolone
JPS5629551A (en) 1979-08-20 1981-03-24 Sumitomo Chem Co Ltd Preparation of optically active threo-3- 3,4- dihydroxyphenyl serine
JPS56104815A (en) 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension
US4421767A (en) * 1981-06-01 1983-12-20 Merrell Toraude Et Compagnie Compounds and methods for treating depression
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
US4480109A (en) * 1982-01-14 1984-10-30 Sumitomo Chemical Company, Limited Process for producing threo-3-(3,4-dihydroxyphenyl)serine
CA1223602A (en) 1983-05-25 1987-06-30 Naohito Ohashi Process for producing 3-(3,4-dihydroxyphenyl) serine
JPS6067420A (ja) * 1983-09-22 1985-04-17 Sumitomo Chem Co Ltd 精神運動興奮抑制剤
JPS6098995A (ja) 1983-11-04 1985-06-01 Microbial Chem Res Found 光学活性３−（３，４−ジヒドロキシフエニル）セリン，およびその誘導体の製造法
JPS6185318A (ja) * 1984-10-04 1986-04-30 Sumitomo Seiyaku Kk 利尿薬
JPS62106015A (ja) * 1985-10-31 1987-05-16 Sumitomo Pharmaceut Co Ltd 抗痴呆薬
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US5240930A (en) * 1987-09-02 1993-08-31 National Research Development Corporation Pharmaceutical compositions for treatment of depression and low blood pressure
US5015564A (en) * 1988-12-23 1991-05-14 Eastman Kodak Company Stabilizatin of precipitated dispersions of hydrophobic couplers, surfactants and polymers
JP2603566B2 (ja) * 1991-03-27 1997-04-23 住友製薬株式会社 尿失禁治療剤
JP3559572B2 (ja) * 1993-01-29 2004-09-02 住友製薬株式会社 急性痛および慢性痛用鎮痛剤
JP3764179B2 (ja) * 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
DE19619510A1 (de) * 1995-05-18 1996-11-21 Sumitomo Chemical Co Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin
GB9510481D0 (en) 1995-05-24 1995-07-19 Orion Yhtymae Oy New catechol derivatives
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6746688B1 (en) * 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
JPH115738A (ja) * 1997-06-15 1999-01-12 Katsuhiro Nishino 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
US6033993A (en) * 1997-09-23 2000-03-07 Olin Microelectronic Chemicals, Inc. Process for removing residues from a semiconductor substrate
US6001607A (en) * 1998-04-13 1999-12-14 Incyte Pharmaceuticals, Inc. Human growth-associated methyltransfeases
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20020177593A1 (en) * 1998-09-30 2002-11-28 Yuji Ishihara Agents and crystals for improving excretory potency of urinary bladder
CN1329487A (zh) * 1998-11-10 2002-01-02 特瓦制药工业有限公司 包含l－多巴乙酯的可分散组合物
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
CN1660108A (zh) * 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
PE20020434A1 (es) * 2000-10-12 2002-06-17 Upjohn Co Metodo de tratamiento de la enfermedad de parkinson
WO2003032969A2 (en) * 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
BR0308556A (pt) * 2002-03-21 2005-05-03 Martin C Hinnz Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
WO2005042475A2 (en) * 2003-10-21 2005-05-12 Sention, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease

Also Published As

Publication number Publication date
EP1948155A2 (en) 2008-07-30
WO2008003028A3 (en) 2008-03-20
US20080015181A1 (en) 2008-01-17
WO2008003028A2 (en) 2008-01-03
ATE548034T1 (de) 2012-03-15
PT1948155E (pt) 2012-06-15
HRP20120479T1 (hr) 2012-07-31
DK1948155T3 (da) 2012-07-02
ES2383768T3 (es) 2012-06-26
EP2363123A1 (en) 2011-09-07
EP1948155B1 (en) 2012-03-07
EP2363124A1 (en) 2011-09-07
US20160106694A1 (en) 2016-04-21
PL1948155T3 (pl) 2012-10-31
EP2363124B1 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
ES2571730T3 (es) Composiciones farmacéuticas que comprenden droxidopa
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
DK1819353T3 (da) Sammensætning til proteasomhæmning
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200900571A1 (ru) Композиции chk1 ингибиторов
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA200800698A1 (ru) Способ стабилизации фармацевтических форм для введения, включающих микроорганизмы
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
EA200970407A1 (ru) Ингибиторы киназ mapk/erk